

decide). We know, however, that a person infected with Zika virus might not have easily observable symptoms. Even if persons accept the possibility of sexual transmission, they might not engage in safe sex practices with asymptomatic infected partners.

If persons understand Zika virus through a mental model informed by dengue or chikungunya, public health officials should address potential confusion, especially in light of differences (e.g., sexual transmission) that might be misunderstood or ignored. Even when not confusing the illnesses, participants clearly conceptualized Zika in comparison with relatively more familiar illnesses. In this way, they operated in similar fashion as consumers encountering novel products do (9,10). Public health messaging might leverage this tendency. If it is easiest to understand a new outbreak in comparison to a previous one, using analogy or direct comparison might be effective but will also require careful emphasis on what is new.

Acknowledgments

We thank staff of ConSUMer of Guatemala, who provided important study support in addition to the contributions described in this letter.

RTI International sponsored the study that produced the information reported here as part of an in-kind donation to the Guatemala Ministry of Public Health and Social Assistance.

About the Author

Dr. Southwell directs the Science in the Public Sphere Program in the Center for Communication Science at RTI International. He also teaches at Duke University and the University of North Carolina at Chapel Hill. His primary research interests include public understanding of science and health and the ways in which the information environment shapes human behavior.

References

- Centers for Disease Control and Prevention. Crisis and emergency risk communication. 2014 edition. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
- Sandman P, Lannard J. Crisis communication: a guide for action. Planning what to say when terrorists, epidemics, and other emergencies strike [cited 2018 Feb 20]. http://www.psandman.com/handouts/AIHA/AIHA_book.pdf
- Glik DC. Risk communication for public health emergencies. *Annu Rev Public Health*. 2007;28:33–54. <http://dx.doi.org/10.1146/annurev.publhealth.28.021406.144123>
- Southwell BG, Reynolds BJ, Fowlie K. Communication, media relations and infectious disease surveillance. In: M'ikanatha NM, Lynfield R, Van Beneden CA, de Valk H, editors. *Infectious disease surveillance*, 2nd ed. Oxford: John Wiley & Sons; 2013. p. 607–17.
- Johnson-Laird P. *Mental models*. Cambridge (MA): Harvard University Press; 1983.
- Jones NA, Ross T, Lynam PP, Leitch A. Mental models: an interdisciplinary synthesis of theory and methods. *Ecol Soc*. 2011;16:art46. <http://dx.doi.org/10.5751/ES-03802-160146>
- Ray SE, Dolina S, Jimenez K, Vazquez N, Ligorria T, Southwell B. Insights regarding Zika virus perceptions in Guatemala: key informant interviews and information environment monitoring: report prepared for Guatemala Ministry of Public Health and Social Assistance. Research Triangle Park (NC): RTI International; 2016.
- Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. *Science*. 1974;185:1124–31. <http://dx.doi.org/10.1126/science.185.4157.1124>
- Jhang JH, Grant SJ, Campbell MC. Get it? Got it. Good! Enhancing new product acceptance by facilitating resolution of extreme incongruity. *J Mark Res*. 2013;49:247–59. <http://dx.doi.org/10.1509/jmr.10.0428>
- Moreau CP, Lehmann DR, Markman AB. Entrenched knowledge structures and consumer response to new products. *J Mark Res*. 2001;38:14–29. <http://dx.doi.org/10.1509/jmkr.38.1.14.18836>

Address for correspondence: Brian G. Southwell, RTI International, Science in the Public Sphere Program, 3040 E Cornwallis Rd, Research Triangle Park, NC 27709, USA; email: bsouthwell@rti.org

Cerebrospinal Fluid Immunoglobulins as Potential Biomarkers of Chikungunya Encephalitis

Marzia Puccioni-Sohler, Luiz Claudio Farias, Mauro Jorge Cabral-Castro, Mariano G. Zalis, Rosangela S. Kalil, Maria Cecília F. Salgado

Author affiliations: Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (M. Puccioni-Sohler, L.C. Farias, M.J. Cabral-Castro, M.G. Zalis); Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro (M. Puccioni-Sohler, R.S. Kalil, M.C.F. Salgado)

DOI: <https://doi.org/10.3201/eid2405.171763>

Chikungunya virus causes fever and severe polyarthritides or arthralgia and is associated with neurologic manifestations that are sometimes challenging to diagnose. We demonstrate intrathecal synthesis of chikungunya antibodies in a patient with a history of acute infection complicated by encephalitis. The specificity of the intracerebral immune response supports early chikungunya-associated encephalitis diagnosis.

Chikungunya virus (CHIKV) is an alphavirus transmitted by infected *Aedes* mosquitoes (*Ae. aegypti* and *Ae. albopictus*) (1). Global expansion epidemics have been

reported (1). The disease is characterized by acute fever, maculopapular rash, headache, and disabling rheumatism (1,2). Neurologic complications may occur, including encephalopathy, encephalitis, myelitis, and Guillain-Barré syndrome (3–5). Differentiating CHIKV infection from other arbovirus infections is difficult because of co-occurring conditions and similar manifestations (3). Detection of viral RNA and specific antibodies in cerebrospinal fluid (CSF) suggests neurotropic evidence of CHIKV (2,3), but whether these antibodies are synthesized locally or derived from blood has not been demonstrated (6,7). We detected intrathecal synthesis of CHIKV IgG by specific antibody index in a case of encephalitis (6).

In January 2016, a 69-year-old woman had sudden fever (38°C), intense generalized arthritis, prostration, and cognitive alterations characterized by forgetting and exchanging words. She used analgesics without relief. After 1 week, a maculopapular rash with intense pruritus appeared on her upper limbs. A few days later, her rash and fever abated, but other symptoms continued. She was referred for consultation 3 months after symptom onset. Physical examination revealed bilateral finger and knee arthritis (online Technical Appendix Figure, <https://wwwnc.cdc.gov/EID/article/24/5/17-1763-Techapp1.pdf>). Neurologic examination showed slow thinking, inattention, and mild confusion. She had a history of dengue and Zika virus infections. Results of a routine blood analysis were unremarkable.

We performed several antibody tests: anti-CHIKV ELISA (IgM and IgG; EUROIMMUN, Luebeck, Germany); Panbio Dengue IgG Indirect ELISA and Dengue IgM Capture ELISA (Panbio, Brisbane, Queensland, Australia); and immunochromatographic assay (GenBody Zika IgG/IgM; Biotech Business, Chungnam, South Korea). Results for specific IgG and IgM are shown in the Table. CSF analysis demonstrated leukocytes 1 cell/mm³; protein 29 mg/dL; glucose 40 mg/dL; blood–CSF barrier function based on albumin quotient 6×10^{-3} ; IgG index 0.43 (reference <0.7); and intrathecal IgG fraction (IgG_{IF}) of total IgG found in CSF, <0% (6,7). In addition, we quantitatively determined the synthesis of specific antibodies by antibody index (AI) (6). We used an ELISA test for DENV IgG and ELISA for CHIKV IgG in paired CSF and serum. We calculated AI as the ratio between the specific IgG and total IgG quotient, considering that there was no intrathecal synthesis of

total IgG (IgG_{IF} <0%). The sample dilutions for dengue were 1:8 for CSF and 1:4,000 for serum. Sample dilutions for CHIKV were 1:2 for CSF and 1:101 for serum (6,8). AI was 1.14 for dengue and 7.24 for CHIKV, with AI reference range <1.5 (online Technical Appendix).

Brain magnetic resonance imaging showed foci with hyperintense signal in the T2-weighted sequences and fluid attenuation inversion recovery bilaterally in subcortical frontoparietal areas. The patient showed substantial progressive improvement of cognitive alterations and arthralgia after starting antiinflammatory treatment; she took nimesulide for 2 months, followed by prednisolone (20 mg/d) with progressive reduction for another 2 months.

Our results demonstrate the quantitation of intrathecal synthesized CHIKV IgG. We diagnosed CHIKV-associated encephalitis on the basis of fever and altered mental status for >24 hours and positive CHIKV IgM antibodies in serum (9). CSF analysis results were unremarkable except for elevated CHIKV AI, the only evidence of brain inflammation. Brain imaging showed unspecific lesions; viral encephalitis may occur without pleocytosis or specific parenchymal abnormalities (9).

The identification of specific etiologies of viral encephalitis may be difficult in arbovirus-endemic areas (3). Co-infections with Zika virus, CHIKV, and DENV are frequent (1,3), and neurologic manifestations may also be similar (4,5). Although this case-patient also had a history of DENV and Zika infection with specific IgG in serum and CSF, we did not detect intrathecal synthesis of DENV antibodies (6–8) as did Puccioni-Sohler et al. in a previous study (8). Our findings show that the quantitation of antibodies synthesized in the brain may be useful in the differential diagnosis of neurologic diseases caused by arboviruses. The detection of specific intrathecal synthesis of antibodies is a known tool for the diagnosis of infections including herpes simplex virus, varicella zoster virus, measles, rubella, neuroborreliosis, and human T-cell leukemia virus type 1 (6–8).

CHIKV has attracted increasing attention because of its spatial spread and the high number of epidemics. Chikungunya has been associated with debilitating arthropathy for months or years after the initial infection, along with severe neurologic complications such as encephalitis (4,5,10). The detection of the etiologic agent of a central nervous system disease may be difficult, considering that PCR results for CHIKV are positive only during the first days of infection (1). In addition, the presence of specific antibodies in CSF may be derived from blood (6,7). The detection of intrathecal synthesis of CHIKV IgG may be useful as a specific laboratorial brain marker for diagnosis of encephalitis and other neurologic complications associated with CHIKV infection. This result provides evidence of viral neurotropism and can be useful for supporting public health.

Table. Results of the detection of IgM and IgG against chikungunya virus, dengue virus, and Zika virus, Brazil, 2016

Target virus	Sample type			
	Serum		Cerebrospinal fluid	
	IgM	IgG	IgM	IgG
Chikungunya	Reactive	Reactive	Reactive	Reactive
Dengue	Not reactive	Reactive	Not reactive	Reactive
Zika	Not reactive	Reactive	Not reactive	Reactive

Acknowledgments

This work was funded by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Edital Programa Pesquisa em Zika, Chikungunya e Dengue—no. 18/2015, and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Edital Apoio Rede Zika Multicêntrico (439928/2016-8), Brazil.

Author contributions: M.P.-S. drafted the study concept and acquired and interpreted data; L.C.F., M.J.C.-C., and M.C.F.S. acquired data and conducted laboratory analyses; M.P.-S., M.G.Z., and M.C.F.S. revised the manuscript; and R.S.K. conducted neuropsychological tests included as supplementary data.

About the Author

Dr. Puccioni-Sohler is an associate professor at the School of Medicine and Surgery, Federal University of Rio de Janeiro State (UNIRIO), Rio De Janeiro, Brazil, and professor of the post-graduation program in Infectious and Parasitic Diseases, Medicine Faculty, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro. Her research interests are tropical neurology and cerebrospinal fluid analysis.

References

- Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. *Lancet*. 2012;379:662–71. [http://dx.doi.org/10.1016/S0140-6736\(11\)60281-X](http://dx.doi.org/10.1016/S0140-6736(11)60281-X)
- Kashyap RS, Morey SH, Chandak NH, Purohit HJ, Taori GM, Dagainawala HF. Detection of viral antigen, IgM and IgG antibodies in cerebrospinal fluid of chikungunya patients with neurological complications. *Cerebrospinal Fluid Res*. 2010;7:12. <http://dx.doi.org/10.1186/1743-8454-7-12>
- Acevedo N, Waggoner J, Rodriguez M, Rivera L, Landivar J, Pinsky B, et al. Zika virus, chikungunya virus, and dengue virus in cerebrospinal fluid from adults with neurological manifestations, Guayaquil, Ecuador. *Front Microbiol*. 2017;8:42. <http://dx.doi.org/10.3389/fmicb.2017.00042>
- Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak SM. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. *AJNR Am J Neuroradiol*. 2008;29:1636–7. <http://dx.doi.org/10.3174/ajnr.A1133>
- Scott SSO, Braga-Neto P, Pereira LP, Nóbrega PR, de Assis Aquino Gondim F, Sobreira-Neto MA, et al. Immunoglobulin-responsive chikungunya encephalitis: two case reports. *J Neurovirol*. 2017;23:625–31. <http://dx.doi.org/10.1007/s13365-017-0535-y>
- Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. *Clin Chim Acta*. 1987;163:319–28. [http://dx.doi.org/10.1016/0009-8981\(87\)90250-6](http://dx.doi.org/10.1016/0009-8981(87)90250-6)
- Sindic CJ, Van Antwerpen MP, Goffette S. The intrathecal humoral immune response: laboratory analysis and clinical relevance. *Clin Chem Lab Med*. 2001;39:333–40. <http://dx.doi.org/10.1515/CCLM.2001.052>
- Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, Castro MJ, Faria LC, Peralta JM. Neurologic dengue manifestations associated with intrathecal specific immune response. *Neurology*. 2009;73:1413–7. <http://dx.doi.org/10.1212/WNL.0b013e3181bd8258>
- Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, et al.; International Encephalitis Consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium. *Clin Infect Dis*. 2013;57:1114–28. <http://dx.doi.org/10.1093/cid/cit458>
- Vijayan V, Sukumaran S. Chikungunya virus disease: an emerging challenge for the rheumatologist. *J Clin Rheumatol*. 2016;22:203–11. <http://dx.doi.org/10.1097/RHU.0000000000000396>

Address for correspondence: Marzia Puccioni-Sohler, Hospital Universitário Gaffrée e Guinle/Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rua Mariz e Barros 775, 20270-004, Rio de Janeiro/RJ, Brazil; email: m_puccioni@yahoo.com.br

Chronic Genotype 3 Hepatitis E in Pregnant Woman Receiving Infliximab and Azathioprine

Caroline Charre, Christophe Ramière, Jérôme Dumortier, Florence Abravanel, Sébastien Lhomme, Rodica Gincul, Caroline Scholtès

Author affiliations: Hospices Civils de Lyon, Lyon, France (C. Charre, C. Ramière, J. Dumortier, R. Gincul, C. Scholtès); Claude Bernard University Lyon 1, Villeurbanne, France (C. Charre, C. Ramière, J. Dumortier, C. Scholtès); INSERM, Lyon (C. Charre, C. Ramière, C. Scholtès); INSERM, Toulouse, France (F. Abravanel, S. Lhomme); Centre Hospitalier Universitaire de Purpan, Toulouse (F. Abravanel, S. Lhomme); Université Paul Sabatier, Toulouse (F. Abravanel, S. Lhomme)

DOI: <https://doi.org/10.3201/eid2405.171845>

Acute hepatitis E virus infection during pregnancy has a high fatality rate in developing countries. Little data are available on chronic infection in pregnant women. We report a case of chronic hepatitis E during treatment with infliximab and azathioprine, without adverse event during pregnancy and with spontaneous resolution after delivery.

Hepatitis E virus (HEV) genotype 1 causes a high number of deaths of pregnant women in developing countries (1). The few reported cases of HEV during pregnancy in industrialized countries (2–5) mainly relate to acute genotype 3 infection. We report the course of autochthonous